niacinamide has been researched along with Intraepithelial Prostatic Neoplasia in 1 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice." | 7.76 | Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010) |
| "To evaluate Sorafenib's efficacy (60 mg/kg/d per os) in preventing the transformation of high grade prostate intraepithelial neoplasia (HGPIN) into adenocarcinoma (ADC) and in inhibiting the onset and progression of poorly differentiated carcinoma (PDC) in transgenic adenocarcinoma mouse prostate (TRAMP) mice." | 3.76 | Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. ( Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bono, AV | 1 |
| Pannellini, T | 1 |
| Liberatore, M | 1 |
| Montironi, R | 1 |
| Cunico, SC | 1 |
| Cheng, L | 1 |
| Sasso, F | 1 |
| Musiani, P | 1 |
| Iezzi, M | 1 |
1 other study available for niacinamide and Intraepithelial Prostatic Neoplasia
| Article | Year |
|---|---|
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease | 2010 |